A Trial For The Study of Falciparum Malaria Protein 013 Administered Via Intramuscular Injection in Healthy Adults
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
A Phase 1, open label clinical study to evaluate the safety, immunogenicity, tolerability and
efficacy of Plasmodium falciparum Malaria Protein 013 (FMP013) combined with (ALF with
QS-21), saponin molecule derived from the bark of Quillaja species (ALFQ)) in healthy adult
volunteers at different doses and dosing schedules.
Phase:
Phase 1
Details
Lead Sponsor:
U.S. Army Medical Research and Development Command